william_potter
william_potter / iStockphoto.com
31 October 2018Big Pharma

Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition

Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
8 May 2018   Japanese pharmaceutical company Takeda has agreed to acquire biotech company Shire for $62 billion.
Asia-Pacific
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
Big Pharma
28 November 2018   Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark

More on this story

Big Pharma
8 May 2018   Japanese pharmaceutical company Takeda has agreed to acquire biotech company Shire for $62 billion.
Asia-Pacific
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
Big Pharma
28 November 2018   Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark

More on this story

Big Pharma
8 May 2018   Japanese pharmaceutical company Takeda has agreed to acquire biotech company Shire for $62 billion.
Asia-Pacific
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
Big Pharma
28 November 2018   Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark